# Kimi K3 / inf-k01

Original final answer, shared by both scoring rounds.

**Bottom line / recommended next action:** From E1, the only defensible conclusion is: “a trait-associated LD block exists near G, containing several correlated candidate variants that span G and H.” It does **not** establish a causal variant, does **not** establish G as the effector gene, and does **not** exclude H, another nearby gene, a distal target, or multiple causal alleles. The next useful step is not more proximity-based argument; it is to define the LD/credible set, then seek **context-matched molecular QTL colocalization** and **endogenous allelic perturbation** that together test the chain variant → regulatory element/transcript → gene → cellular phenotype → trait.

## 1) Evidence → inference → conclusion chain for E1

| Evidence location | What is observed | Licensed inference | Not licensed inference | Interim conclusion |
|---|---|---|---|---|
| E1 | Well-controlled GWAS; lead noncoding SNP near gene G | A locus is associated with the trait; confounding is argued to be controlled by design; lead SNP is a tag or candidate within an associated haplotype | That the lead SNP is causal; that “noncoding” means regulatory; that association direction/magnitude equals mechanism | Association is real as a statistical locus, assuming GWAS control is adequate |
| E1 | Several linked variants span G and H | LD makes multiple variants statistically indistinguishable by marginal association; causal variant may be any typed/imputed/untagged variant in the block, or more than one variant may contribute | Gene assignment by nearest gene; excluding H; excluding variants outside G/H if they regulate the locus; assuming one causal variant | Causal-variant and effector-gene status are unresolved |
| E1 | No functional or colocalization data supplied | No current evidence linking genotype to chromatin activity, transcription, splicing, protein abundance, cell state, or organismal phenotype | Treating absence of colocalization/perturbation as absence of mechanism; citing synthetic figures as validation | Mechanism is unknown; all functional claims are hypotheses |
| E1 | Figures are synthetic teaching materials; no unreported validation | They can illustrate concepts only | Using them as empirical support | Do not cite them as results |

**Explicit chain allowed now:**  
E1 association + adequate GWAS control → “some allele(s) in this LD region are correlated with trait liability.” Because lead SNP is noncoding and near G → “regulatory mechanism involving G is a reasonable hypothesis.” Because linked variants span G and H → “the causal variant may affect G, H, both, neither directly, or a distal element; LD prevents naming it.” Because no colocalization/functional data → “no effector gene or causal nucleotide is established.”  
**Final E1-only conclusion:** associated locus; unresolved causal variant; unresolved effector gene; mechanism unproven.

## 2) Linkage/LD: what the GWAS signal is and is not

**Concept:** GWAS tests marginal genotype–trait correlation. Recombination creates linkage disequilibrium (LD), so a causal allele is correlated with neighboring alleles. The “lead SNP” is usually the most statistically tagged proxy, not necessarily the causal nucleotide.

**Can establish:** a robust genomic interval for follow-up if population structure, relatedness, genotyping/imputation, multiple testing, and phenotype/model issues are controlled; approximate effect direction for the tested allele.

**Cannot establish:** causality of the lead SNP; independence from correlated variants; the relevant tissue/cell state; the effector gene; whether one or several causal variants exist; whether the true causal allele was even assayed.

**Applied to E1:** the lead noncoding SNP near G is a signpost. Because linked variants span G and H, the associated haplotype carries sequence differences in/around both genes. Physical adjacency of the lead SNP to G is weak evidence and is easily misleading: noncoding elements can act over distance, skip the nearest promoter, or regulate multiple genes.

## 3) Statistical fine mapping: narrowing, not proving

**Concept:** Use conditional/joint analysis, LD from an ancestry-matched reference, imputation quality, annotations as priors, and Bayesian credible sets to assign posterior probabilities that variants are causal under a specified model.

**Can establish, conditionally:** which variants are plausible drivers if model assumptions hold; whether one signal remains after conditioning; whether multiple independent signals exist; a prioritized credible set for experiments.

**Cannot establish:** functional effect; tissue relevance; effector gene; true causality. Posterior probabilities are model-relative: misspecified LD, ancestry mismatch, allelic heterogeneity, untyped causal variants, genotyping error, selection, winner’s curse, or correlated phenotypes can produce a confident but wrong “top variant.”

**Applied to E1:** fine mapping should include all linked variants spanning G and H, check coding/splice/regulatory consequences rather than assuming “noncoding,” test for secondary signals after conditioning on the lead SNP, and report a credible set plus sensitivity to LD/reference panel. Output should be: “variants {…} have posterior mass under assumptions A,” not “SNP X causes trait via G.”

## 4) Colocalization: same signal, same context?

**Concept:** Test whether the trait association and a molecular phenotype—eQTL/sQTL/pQTL, chromatin accessibility, promoter/enhancer activity, 3D contact, methylation—share the same causal variant in a trait-relevant cell type/state.

**Can establish:** support for a shared genetic signal between disease risk and a molecular trait; nominate an effector transcript or regulatory element if GWAS and QTL signals colocalize and the tissue/context is relevant.

**Cannot establish alone:** that the variant perturbs the element; that the element changes the nominated gene; that gene change causes disease; or that the assayed tissue is causal. Standard colocalization often assumes a single causal variant per region; multiple causal variants, LD mismatch, low QTL power, splice/isoform misspecification, cell-state mismatch, batch effects, and pleiotropy can yield false positive/negative colocalization. Non-colocalization in an irrelevant tissue does not refute causality.

**Applied to E1:** there is no colocalization evidence. Therefore claims such as “the GWAS allele lowers G expression” or “H is excluded” are unsupported. The decisive question is contextual: in the cell type/state implicated by disease biology, do GWAS and molecular QTL signals share a variant, and does allelic imbalance/reporter/CRISPR evidence agree?

## 5) Functional perturbation: testing necessity and sufficiency

**Concept:** Directly perturb candidate nucleotides/elements/genes and measure molecular, cellular, and—if possible—trait-relevant outcomes. Hierarchy: variant → element activity/TF binding/chromatin → transcription/splicing of G or H → cell phenotype → organismal trait.

**Can establish, when done endogenously and with controls:** whether a specific allele is sufficient/necessary for a regulatory effect; which gene’s expression changes after element perturbation; whether changing G or H changes a proximal cell phenotype; directionality and dosage sensitivity.

**Cannot guarantee:** organismal disease causality, developmental timing, correct cell type, compensatory/redundant enhancers, physiological dosage, absence of CRISPR off-targets, or relevance of immortalized models. Motif disruption is suggestive but neither necessary nor sufficient by itself. A coding/splice variant among linked variants would demand different assays than an enhancer SNP.

**Applied to E1:** no perturbation data exist, so no allele has been shown necessary or sufficient for anything. Proposed experiments: endogenous allele replacement/base/prime editing of credible-set variants in relevant cells; CRISPRi/a tiling of candidate elements; measure allele-specific expression of G and H, chromatin accessibility/contact, and downstream phenotype; then perturb G and H individually/jointly to test whether their expression changes phenocopy the allelic effect.

## 6) Correct relationships among the concepts

**Linkage** defines the blurred window: many correlated variants travel together. **Fine mapping** sharpens the statistical candidate set under assumptions. **Colocalization** connects that candidate set to a molecular readout in the right context. **Functional perturbation** tests causal sufficiency/necessity along a mechanistic chain. They are complementary, not interchangeable: high posterior fine-mapping probability without function is still only statistical; strong enhancer activity without GWAS colocalization may be irrelevant to trait; eQTL colocalization without perturbation may reflect LD or assay context; perturbation of G without variant-to-element evidence leaves the causal nucleotide unproven.

## 7) Alternatives and limits for the supplied locus

- **G is effector via lead/credible SNP:** plausible but unproven; requires colocalization and perturbation.
- **H is effector:** equally allowed by E1 because linked variants span H.
- **Both G and H / gene desert / distal target:** possible if regulatory element contacts multiple promoters or causal gene is outside the spanned segment.
- **Multiple causal variants/allelic heterogeneity:** marginal lead SNP may mask compound signals; conditioning required.
- **Untyped causal variant:** lead SNP tags a structural/rare allele; sequencing needed.
- **Context dependence:** causal effect only in a stimulated/developing/rare cell state; baseline adult tissue assays may be null.
- **Synthetic figures:** teach possibilities only; they cannot validate any branch.

## 8) What would change the recommendation

Move from “associated locus” to “candidate causal mechanism” only if: ancestry-matched fine mapping yields a small credible set; trait-relevant eQTL/sQTL/chromatin data colocalize with the same signal; endogenous allele editing changes chromatin and expression of the same gene that colocalizes; and perturbing that gene changes a trait-relevant cellular phenotype in the same direction. Until then, report E1 as: **genome-wide significant LD block near G/H; causal variant and effector gene undetermined; functional and colocalization evidence absent.**
